NF2 and neoplasm: In a recent study, Hylebos et al. (106) performed whole exome sequencing (WES) of tumor and germline DNAs of ten MPM patients and confirmed the mutation described by Bueno et al. Selected tumor-specific variants of ctDNA were detected in serum samples using ddPCR (Droplet Digital PCR), but the mutation in NF2 was clearly and reproducible detectable in only one patient (fraction of mutated DNA = 0.8%).